177 related articles for article (PubMed ID: 36196499)
1. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
[TBL] [Abstract][Full Text] [Related]
2. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
[TBL] [Abstract][Full Text] [Related]
3. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
[TBL] [Abstract][Full Text] [Related]
4. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
[TBL] [Abstract][Full Text] [Related]
5. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
6. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
[TBL] [Abstract][Full Text] [Related]
7. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
[TBL] [Abstract][Full Text] [Related]
8. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
[TBL] [Abstract][Full Text] [Related]
9. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
[TBL] [Abstract][Full Text] [Related]
10. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
[TBL] [Abstract][Full Text] [Related]
12. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
[TBL] [Abstract][Full Text] [Related]
14. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
Samuel CA; Turner K; Donovan HAS; Beckjord E; Cardy A; Dew MA; van Londen GJ
Support Care Cancer; 2017 Dec; 25(12):3723-3731. PubMed ID: 28681126
[TBL] [Abstract][Full Text] [Related]
15. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
[TBL] [Abstract][Full Text] [Related]
16. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
[TBL] [Abstract][Full Text] [Related]
17. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
18. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
20. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
